Department of Economics and Business Economics

Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial:

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Alyna Turner, The University of Newcastle
  • ,
  • Andrea Baker, Queensland Centre for Schizophrenia Mental Health Research, The Park, Centre for Mental Health, Wacol, Australia.
  • ,
  • Olivia M Dean, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia2Department of Medicine, University of Melbourne, Melbourne, Australia29Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.
  • ,
  • Adam J Walker, Geelong Hospital, Geelong, Australia.
  • ,
  • Seetal Dodd, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia2Department of Medicine, University of Melbourne, Melbourne, Australia29Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.
  • ,
  • Susan M Cotton, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • ,
  • James G Scott, Queensland Centre for Schizophrenia Mental Health Research, The Park, Centre for Mental Health, Wacol, Australia., Metro North Mental Health Service, School of Population Health, The University of Queensland, Herston, Australia., Univ Queensland, University of Queensland, Queensland Brain Inst, Mental Health Programme, QIMRBerghofer Medical Research Institute
  • ,
  • Bianca E Kavanagh, Geelong Hospital, Geelong, Australia.
  • ,
  • Melanie M Ashton, Geelong Hospital, Geelong, Australia.
  • ,
  • Ellie Brown, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • ,
  • John J McGrath
  • Michael Berk, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia2Department of Medicine, University of Melbourne, Melbourne, Australia29Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.

OBJECTIVES: Garcinia mangostana Linn. ("mangosteen") pericarp contains bioactive compounds that may target biological pathways implicated in schizophrenia. We conducted a double-blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp, compared to placebo, in the treatment of schizophrenia.

METHODS: People diagnosed with schizophrenia or schizoaffective disorder (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition), recruited across 2 sites (Brisbane and Victoria, Australia), were randomized to receive 24 weeks of adjunctive mangosteen pericarp (1,000 mg/day) or matched placebo. The primary outcome measure was the Positive and Negative Symptom Scale total score. Secondary outcomes included positive and negative symptoms, general psychopathology, clinical global severity and improvement, participant reported overall improvement, depressive symptoms, functioning, quality of life, and safety data at 24 and 28 weeks (4 weeks postdiscontinuation). Data were collected from July 2016 to February 2019.

RESULTS: Baseline assessments were conducted on 148 people (mangosteen = 74, placebo = 74); data analyses were conducted on 136 (92%) participants with postbaseline data. The treatment group had significantly higher symptom severity compared to placebo, and both groups significantly improved on all symptom, functioning, and quality of life measures over time. No between-group differences were found for the rate of change between baseline and 24 or 28 weeks.

CONCLUSION: Despite promising preclinical and clinical work, our results do not support mangosteen pericarp extract as an adjunctive treatment for schizophrenia or schizoaffective disorder.

Translated title of the contributionPéricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placebo
Original languageEnglish
JournalCanadian Journal of Psychiatry
Volume66
Issue4
Pages (from-to)354-366
Number of pages13
ISSN0706-7437
DOIs
Publication statusPublished - Apr 2021

    Research areas

  • Garcinia mangostana Linn, clinical trial, inflammation, mangosteen, mental disorders, oxidative stress, psychiatry, schizoaffective disorder, schizophrenia, treatment

See relations at Aarhus University Citationformats

ID: 207080663